Findings from a nationwide population-based study revealed that patients diagnosed in hipec centers had better odds of undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) and improved survival rates before 2016. However, after national efforts to increase awareness and improve referral networks, these differences were no longer present between patients diagnosed in hipec and referring centers from 2016 to 2021, indicating equal access to care and similar chances of survival at a national level.
© 2024. The Author(s).